What Mingde Capital does

Mingde Capital (明德资本) is a privately-held, Beijing-based financial advisory (FA) firm founded in 2022 by a team of senior investment bankers, investors, and operators led by CEO Zhou Xiang (formerly 14 years at Huaxing Capital and a stint at Legend Capital, active in China's FA industry since 2006) and Partner Hu Mingyi (former head of Huaxing's healthcare FA group, founder of Genosys). The firm operates as a partnership-model advisor providing capital market services — primarily private equity financing mandates and M&A transaction advisory — to growth-stage startups in China's new-economy sectors, with explicit focus areas including artificial intelligence (large models, embodied AI, AI for Science, AI compute), frontier technology (controlled nuclear fusion, quantum computing, brain-computer interfaces, synthetic biology), advanced manufacturing (semiconductors, aerospace, new materials, new energy), and healthcare/life sciences.

Mingde's business model is professional services revenue in the form of success-based advisory fees on closed financings and M&A deals. Disclosed deal flow includes exclusive-FA mandates such as Deep Principle's multi-round financings in AI for Science, Blue Crystal Microbes' roughly 1 billion RMB B4 round in synthetic biology, Chaiting Technology's spin-out financing exceeding 1 billion RMB in cybersecurity, Jinjing Yunhua's near-100 million RMB Series B in AI security, Kewoke Technology's hydrogen production diaphragm rounds, and Xuanjing Bio and NewPro biotech mandates. Pricing is negotiated per engagement and not publicly disclosed.

The firm is currently extremely lean (1-10 employees), operates from a single Beijing headquarters (Room 602, Fuxing International Center, Chaoyang District), and is exclusively domestic in geographic scope. Go-to-market is partner-led direct engagement, supplemented by a corporate website, a WeChat Official Account (明德资本 Mingde Capital), a public Mingde Deals showcase page, and an active recruiting channel. Mingde does not offer software products, APIs, or proprietary technology platforms; the firm's stated moat rests entirely on senior-partner pedigree, sector relationships, and execution track record rather than on technology or scale.

Name

Mingde Capital

Legal name

明德资本 (Mingde Capital)

Website

https://mingdecapital.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

1–10 employees

Short description

Mingde Capital is a Beijing-based financial advisory firm founded in 2022 that serves China's new-economy startups across AI, frontier technology, advanced manufacturing, and healthcare by providing exclusive private financing and M&A advisory mandates through a partner-led engagement model.

Ownership category

akta.pro rank

Product category

Financial Advisory Services

NAICS

Securities, Commodity Contracts, and Other Financial Investments and Related Activities (523)

SIC

Security Brokers, Dealers & Flotation Companies (6211)

akta.pro primary industry

Capital Raising Advisory (Equity & Equity-Linked) (FSAEAGAC)

akta.pro secondary industries

Corporate Finance & Capital Advisory (BPAHADAB), Capital Markets Advisory (IPO Readiness, SPAC, ECM/DCM Advisory) (BPAHAOAL)

Keywords

• Financial advisory services
• Private equity financing
• Mergers and acquisitions advisory
• Capital market advisory
• Venture capital advisory

Headquarters

HQ city

Beijing

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales

Revenue model

1. Financial Advisory Fees: Mingde Capital generates revenue through financial advisory fees for providing capital market services to startups, including private equity financing and M&A transaction facilitation. The firm operates as a Financial Advisor (FA) serving new economy companies seeking growth capital.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Mingde Capital provides financial advisory services to startups and growth-stage companies in new-economy sectors (AI, frontier technology, advanced manufacturing). The firm acts as exclusive financial advisor on private equity financing rounds and M&A transactions, with senior partners deeply involved in every engagement, delivering long-term, objective capital market counsel and investor access.

Product overview

Mingde Capital is a financial advisory (FA) firm founded in 2022, providing capital market advisory services to startups and emerging companies. The company operates primarily as a service-based business rather than a software product company. Their core offering is financial advisory services helping companies secure financing and navigate M&A transactions. The company does not appear to offer discrete software products or technology platforms — all extracted content relates to their advisory services and deal-making activities.

Differentiator

Problem solved

Functional benefit

Products and services

• Financial Advisory Services (Private Equity Financing) Exclusive financial advisory for private equity financing rounds (Pre-Seed through Pre-IPO) for new-economy startups in AI, frontier technology, advanced manufacturing, and healthcare/life sciences. The firm is engaged on a per-deal basis, supports valuation negotiations, investor sourcing, and closing, and accumulates a multi-round track record with many clients (e.g., Deep Principle, Blue Crystal Microbes, Bai Yao Technology, Xuanjing Bio, Innoway Qixing, Yinghua Chenrui, Jinjing Yunhua).
• Financial Advisory Services (M&A Transactions) M&A transaction advisory and execution for startup and growth-stage clients, including split-financing structures and divestiture-related capital advisory (e.g., Chaiting Technology's split financing exceeding RMB 1 billion), delivered by senior partners with multi-decade track records from Huaxing Capital.
• Strategic Capital Markets Advisory Long-term, objective strategic counsel on capital markets, including financing planning, investor positioning, and sustainable growth financing strategies for new-economy clients, designed to address capital cycles and to surface and support future industry leaders over multi-year horizons.
• Healthcare and Life Sciences Financial Advisory Sector-specialized financial advisory for biotech, synthetic biology, pharma R&D, and medical device startups, led by Partner Hu Mingyi; covers financing rounds for clients such as Blue Crystal Microbes, Bai Yao Technology, Xuanjing Bio, Yinghua Chenrui, NewPro, and Shi Qi Biochemical, applying domain expertise to navigate regulatory and long R&D-cycle realities of healthcare.

Quantifiable outcome

• 500+ closed transactions across sectors and stages
• +2 more outcomes

Named customers19 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators5 records

Recent moves6 records

Expansion highlights4 records

Broad incumbents

• Houlihan Lokey: Global independent advisory firm with strong M&A and capital-raising practices; comparable to Mingde Capital in senior-led, relationship-driven advisory execution and growth-company financing focus, but operating at much larger scale and serving cross-border mandates Mingde does not cover from China.
• CICC (中金公司): China's flagship full-service investment bank with broad coverage including ECM, M&A and growth-equity advisory — overlaps with Mingde Capital on financing advisory to Chinese growth companies, though CICC operates as a much broader franchise and competes for larger-cap and cross-border mandates Mingde does not service.

Direct peers

• China Renaissance (华兴资本): China's leading independent boutique advisor and Mingde Capital's most direct competitor; Mingde's founders (Zhou Xiang and Hu Mingyi) were former senior leaders at China Renaissance's financial advisory business unit, and the firms compete for the same VC/PE financing and M&A mandates across AI, frontier tech and advanced manufacturing.
• eCapital (易凯资本): Long-standing Chinese boutique advisor focused on growth-stage and new-economy financings in healthcare, consumer, and technology — directly comparable to Mingde Capital in target clients (Chinese VC-backed startups), service mix (PE financing + M&A advisory), and reputation-driven, senior-led delivery model.
• Lattice Capital (光源资本): Beijing-based Chinese FA boutique advising startups on growth-equity financings and strategic transactions; competes head-to-head with Mingde for AI, SaaS and frontier-tech mandates and shares a similar boutique, partner-led approach to serving new-economy issuers.
• Hina Group (汉能资本): One of China's earliest financial advisor brands, serving new-economy and TMT clients with a mix of growth-equity FA, M&A advisory and fund services — comparable to Mingde Capital in that both target Chinese growth-company issuers and compete on premium, relationship-driven mandates.
• Index Capital (指数资本): Chinese boutique advisor focused on venture and growth-stage financing rounds for technology-enabled companies; directly comparable to Mingde Capital in deal-size sweet spot (Series A through C), sector overlap (AI, deep tech) and exclusive-FA mandate model.
• Thaihot Capital (泰合资本): Boutique Chinese FA firm focused on growth-stage rounds and M&A for new-economy companies in consumer, healthcare and tech; comparable to Mingde Capital in target client (Chinese VC-backed growth companies), exclusive-FA positioning, and senior-partner-led engagement model.

Emerging players

• Zero2IPO Group (清科): China-based venture research, data and FA platform serving PE/VC transactions; comparable to Mingde Capital as a Chinese FA provider to growth-stage startups, but distinguished by its research, ranking and database franchise plus broader scope beyond pure-play advisory.
• 36Kr Capital: Chinese tech-media-plus-FA platform that connects startups to investors and provides financial advisory on venture and growth-stage rounds; comparable to Mingde Capital as a Chinese FA intermediary for new-economy issuers, with a media-driven origination channel that Mingde lacks.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mingde Capital